Low-dose streptokinase added to emergency artery opening in heart attack
Tests streptokinase given with artery-opening treatment in adults having an ST-elevation heart attack.
Plain-language title generated from the registry record
Registry title: IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
Key facts
- Where
- Xuzhou, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 who are having a heart attack with ST-segment elevation (STEMI) that started within the last 12 hours. It tests a low dose of recombinant streptokinase given into the heart artery together with the stent procedure (pPCI).
- Age
- 18 to 75 years
- Sex
- Women and men can join.
- Disease stage
- Acute STEMI diagnosed by the guidelines, with symptoms that began within 12 hours and a TIMI thrombus grade of 2 or more.
- Earlier treatment
- People who have taken blood-thinning pills by mouth continuously for 3 months or more cannot join.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Cardiogenic shock, cardiac rupture or acute aortic syndrome that cannot be ruled out
- High risk of bleeding or other reason not to have clot-dissolving treatment
- Body weight under 40 kg (88 lb) or over 200 kg (441 lb)
- Allergy to recombinant streptokinase or contrast agents
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07875179, who can take part
Where in China
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaContact: Yuan Lu, M.D.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Affiliated Hospital of Xuzhou Medical University
- Trial code
- NCT07875179
- Record updated
- 15 October 2026
- Original description
This is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).Read full original descriptionShow less
Impact of Intra-procedural pPCI Combined With Low-dose Recombinant Streptokinase on Coronary MicroVascular Dysfunction and Events in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Multicenter, Prospective, Pragmatic, Randomized Controlled Trial Protocol
This is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
A total of 3,300 patients will be enrolled, consisting of a core randomized study (300 patients, 1:1 ratio to pPCI + recombinant streptokinase vs. pPCI alone) and an extended observational study (3,000 patients receiving pPCI + recombinant streptokinase). The primary outcome measure is the coronary angiography-derived index of microcirculatory resistance (caIMR) immediately after the procedure. Secondary outcomes include the incidence of major adverse cardiovascular events (MACE) at 1 year, TIMI flow grade, corrected TIMI frame count (CTFC), and myocardial salvage index.
The study duration is 24 months after the first patient enrollment, with follow-up visits scheduled at Day 5, Week 4, Week 12, Week 24, and Week 52.
Inclusion: Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) according to the guidelines; Onset of STEMI symptoms within 12 hours; TIMI thrombus grade ≥ 2; Age 18 to 75 years, inclusive, gender (male or female); Written informed consent obtained from the patient or their legal representative.
Exclusion: Previously known severe heart disease; Severe cardiovascular diseases, including cardiogenic shock, cardiac rupture, or acute aortic syndrome (e.g., aortic dissection, coronary artery dissection, or aneurysm) that cannot be excluded; Known coronary artery disease unsuitable for revascularization; High risk of bleeding or other contraindications to thrombolytic therapy; Allergy to recombinant streptokinase or contrast agents; Other systemic diseases, including life expectancy < 1 year due to other diseases, severe liver or kidney dysfunction, hematological diseases, acute pancreatitis, diabetic retinopathy, consciousness disorders, or malignant tumors; Any condition that the investigator considers unsuitable for participation in this study; Pregnant or breastfeeding women; Patients with ventricular fibrillation requiring cardiopulmonary resuscitation or refractory to 3 electrical defibrillation attempts; Continuous oral anticoagulant use for ≥ 3 months; Body weight < 40 kg or > 200 kg.